-
Insights into Drug Discovery and Development 2025
Here we interview our Director of Medicinal Chemistry, Anita Wegert, for her insights into drug discovery and development for 2025. This interview was conducted an interviewer from the Drug Discovery and Development Europe event and we were able to share our expertise. Curious how our insights can help your next project?
-
Symeres and Yoneda Labs Use AI to Optimize Cross-Coupling Reactions
San Francisco, May 29, 2025 – Yoneda Labs, a leader in computational tools for reaction optimization, has successfully collaborated with Symeres, a leading transatlantic, small molecule contract research and manufacturing organization. The aim was to optimize transition metal catalyzed cross-coupling reactions to improve reaction yield and efficiency utilizing Yoneda Labs’ cutting-edge software.
-
J. Med. Chem. Publication: Development of a 1,2,4-Triazole-Based Lead Tankyrase Inhibitor: Part II
In this follow-up article, co-published with Oslo University Hospital, we report further development and optimization of 1,2,3-triazole-based tankyrase inhibitors. Through X-ray crystallography supported SAR analysis, we synthesized a series of novel TNKS inhibitors with improved ADME/PK profiles, exhibiting antiproliferative efficacy in colorectal cancer cell lines. Click on the link below for a short summary of this publication.
-
Meet the Organix Director, Mario Gonzalez
We are pleased to share a conversation with Dr. Mario Gonzalez, a Director at Organix, as he reflects on his journey from Argentina to Massachusetts and provides valuable career insights in celebration of his 30 years with the company.
-
New Production Lines D1 and D2 at our Prague site!
The new production lines D1 and D2 were launched for the first time in May 2024 at the Prague site. The first batch of 11 kg of API was produced in the following weeks, and the tremendous efforts of the many people involved in planning the entire production line have finally paid off. Since the production line was launched, all equipment has been continuously utilized.
-
Reliable Tablet Formulation at Exemplify!
We at Symeres pride ourselves on a stellar track record in drug-substance development. For our clients that are looking to rapidly move through phase-appropriate clinical tablet formulation development, Exemplify is the perfect place to start for small-scale to large-scale pharma companies. Our cGMP suites are specially equipped to support everything from pre-tox formulation to first-in-human (FIH) trials and commercially ready formulation.
-
Peter Molenveld’s 25th Anniversary with Symeres
Recently, our colleague Peter Molenveld celebrated his 25th anniversary with Symeres. Peter participated in an interview where he shared about his time with Symeres and his growth here as a chemist to leadership within the organization, as well as about his role as secretary at the Royal Netherlands Chemical Society (KNCV).
-
New NMR Technology – Meet “Maggie”
Nuclear Magnetic Resonance (NMR) Spectroscopy is a powerful analytical tool well known to all organic chemists and to anyone that works in pharmaceuticals. By placing a sample dissolved in deuterated solvent into a strong magnetic field (roughly 4000x the strength of Earth’s magnetic field) and pulsing it with radio frequencies, the chemist is given an enormous amount of information from the identity and placement of functional groups to relative stereochemistry of diastereomers. Recently, Exemplify added NMR to our expanding list of capabilities.
-
Symeres announces leadership evolution
Symeres announces the evolution of its leadership team ahead of the company’s next phase of development. After nearly three decades at the helm, Symeres’ co-founders, Dr. Eelco Ebbers (CEO) and Dr. Frank Leemhuis (Head of Corporate Development), have decided to step back from their current executive roles.
-
Official opening of new Oncolines home, the Marie Curie Building at the Pivot Park in Oss, The Netherlands
After months of dedication and collaboration, the official opening of the Marie Curie building at the Pivot Park in Oss was opened on Sep 19th, 2024. The Marie Curie building is a multitenant laboratory building which houses Oncolines B.V., the in vitro biology services laboratory of Symeres. Read more about this exciting development!
-
J. Med. Chem. Publication: Preclinical Lead Optimization of a 1,2,4-Triazole-Based Tankyrase Inhibitor
In collaboration with Oslo University Hospital, we report the synthesis and biological activity of novel 1,2,3-triazole-based tankyrase inhibitors. Through a modular synthetic pathway and X-ray crystallography supported SAR analysis, we synthesized a series of novel TNKS inhibitors with improved ADME profiles, exhibiting antiproliferative efficacy in colorectal cancer cell lines. Click on the link below for a short summary of this publication.
-
New video of our Solid-State Center of Excellence
In this new video our colleagues Gabriella Pizutti, Chantalle van Berkel, and Eva Verhofstad, will give you an exciting lab tour through the Symeres Solid-State Centre of Excellence, located at the Symeres site in Weert, the Netherlands. You will learn more about PhysChem Properties, Solid Form Screening, Crystallization, Crystal Habit, Pre-formulation, and Formulation. Feel free to contact us via the contact form on this website if you would like to learn more about our Solid-State capabilities.
Feel free to contact us!
Curious to know more about what can we do for you? Get in touch and let’s start a conversation.
